共 223 条
[1]
Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-249
[2]
Ferlay J(2021)Targeted immunotherapies in gastrointestinal cancer: from molecular mechanisms to implications Front Immunol 12 2074-2084
[3]
Siegel RL(2012)Preoperative chemoradiotherapy for esophageal or junctional cancer N Engl J Med 366 1191-1203
[4]
Laversanne M(2021)Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer N Engl J Med 384 11-20
[5]
Soerjomataram I(2006)Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 3392-3400
[6]
Jemal A(2019)Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer J Clin Oncol 37 2324-2331
[7]
Wang DK(2022)Adjuvant chemotherapy for gastric cancer patients with mismatch repair deficiency or microsatellite instability: Systematic Review and Meta-Analysis Ann Surg Oncol 29 255-265
[8]
Zuo Q(2023)Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study J Clin Oncol 41 943-952
[9]
He QY(2019)KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer Future oncology (London, England) 15 2465-2473
[10]
Li B(2022)MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer Future oncology (London, England) 18 95-104